Skye Bioscience Securities Fraud Investigation

A class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the “Class Period”), inclusive.

Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, contact Berger Montague.

Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.

The complaint asserts that, throughout the Class Period, Defendants failed to disclose that: (i) the efficacy of nimacimab, Skye’s lead product candidate, was lower than what had been represented to investors; and (ii) as a result, the drug’s clinical and commercial potential had been overstated.

On October 6, 2025, Skye issued a press release announcing topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, disclosing that that the primary endpoint of 8% difference in weight loss compared to placebo had not been met. Following these disclosures, Skye’s stock price declined $2.85 per share, or 60%, closing at $1.90 on October 6, 2025.

If you are a Skye investor and would like to learn more about this action, please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.